A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.

ABSTRACT:

Objective

A phase 2, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab for the prevention of episodic migraine in Japanese patients was conducted.

Background

Previous global clinical studies have demonstrated the efficacy of erenumab in the prevention of migraine.

Methods

Patients were randomized to placebo or erenumab 28, 70, or 140 mg administered subcutaneously once per month for 6 months. The primary endpoint was change from baseline in mean monthly migraine days over months 4-6 of the double-blind treatment phase. Secondary endpoints included the proportion of patients achieving ≥50% reduction from baseline in mean monthly migraine days (≥50% response) and change from baseline in mean monthly acute migraine-specific medication

SUBMITTER: Sakai F 

PROVIDER: S-EPMC6900095 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature